BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8076188)

  • 1. [Molecular markers in breast cancer: practical aspects and morphologic evaluation].
    Charpin C; Pellissier JF
    Bull Acad Natl Med; 1994 Mar; 178(3):475-87; discussion 487-93. PubMed ID: 8076188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors.
    Charpin C; Devictor B; Bonnier P; Andrac L; Lavaut MN; Allasia C; Piana L
    J Pathol; 1993 Aug; 170(4):463-70. PubMed ID: 8410496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytosol cathepsin D in Thai women with breast cancer.
    Chearskul S; Bhothisuwan K; Tunsuphasiri V; Churinthrapun M; Keyanond V; Ornrheabroi S
    J Med Assoc Thai; 1996 Oct; 79(10):654-60. PubMed ID: 8997001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodetection of HER-2/neu protein in frozen sections evaluated by image analysis: correlation with overall and disease-free survival in breast carcinomas.
    Charpin C; Bonnier P; Devictor B; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1993; 13(3):603-12. PubMed ID: 8100412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
    Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M
    Br J Cancer; 1999 May; 80(3-4):419-26. PubMed ID: 10408848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin D may help in discriminating node-negative breast cancer patients at risk for local-regional recurrence.
    Ardavanis A; Scorilas A; Loukeri A; Gerakini F; Pissakas G; Missitzis I; Apostolikas N; Yiotis I
    Anticancer Res; 1998; 18(4B):2885-90. PubMed ID: 9713481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen value as a marker in breast cancer.
    Narita D; Cimpean AM; Anghel A; Raica M
    Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays.
    Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
    J Pathol; 1998 Apr; 184(4):401-7. PubMed ID: 9664906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
    Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
    Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of searching for additional prognostic factors in combination with Nottingham Prognostic Index in breast carcinoma patients].
    Jakić-Razumović J; Corić M; Vrbanec D; Babić D; Hlupić L; Belev B
    Lijec Vjesn; 2005; 127(1-2):3-7. PubMed ID: 16145866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
    Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
    Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
    Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
    Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.